159 related articles for article (PubMed ID: 7713158)
1. Diurnal alteration in opiate effects on the hypothalamo-pituitary-adrenal axis: changes in the mechanism of action.
Kiem DT; Fekete MI; Makara GB
Eur J Pharmacol; 1995 Jan; 272(2-3):145-50. PubMed ID: 7713158
[TBL] [Abstract][Full Text] [Related]
2. Chronic naloxone-induced supersensitivity affects neither tolerance to nor physical dependence on morphine at hypothalamus-pituitary-adrenocortical axis.
Alcaraz C; Vargas ML; Milanés MV
Neuropeptides; 1996 Feb; 30(1):29-36. PubMed ID: 8868296
[TBL] [Abstract][Full Text] [Related]
3. Differences in hypothalamo-pituitary-adrenocortical activity in the rat after acute and prolonged treatment with morphine.
Buckingham JC; Cooper TA
Neuroendocrinology; 1984 May; 38(5):411-7. PubMed ID: 6328347
[TBL] [Abstract][Full Text] [Related]
4. Chronic naloxone treatment induces supersensitivity to a mu but not to a kappa agonist at the hypothalamus-pituitary-adrenocortical axis level.
Alcaraz C; Vargas ML; Fuente T; Milanés MV
J Pharmacol Exp Ther; 1993 Sep; 266(3):1602-6. PubMed ID: 8396640
[TBL] [Abstract][Full Text] [Related]
5. Effects of naloxone on hypothalamo-pituitary-adrenocortical activity in the rat.
Buckingham JC; Cooper TA
Neuroendocrinology; 1986; 42(5):421-6. PubMed ID: 3010154
[TBL] [Abstract][Full Text] [Related]
6. Consequences of prenatal morphine exposure on the hypothalamo-pituitary-adrenal axis in the newborn rat: effect of maternal adrenalectomy.
Lesage J; Grino M; Bernet F; Dutriez-Casteloot I; Montel V; Dupouy JP
J Neuroendocrinol; 1998 May; 10(5):331-42. PubMed ID: 9663647
[TBL] [Abstract][Full Text] [Related]
7. Naloxone does not reverse the inhibitory effect of morphine on luteinizing hormone secretion in prepubescent male rats.
Cicero TJ; Nock B; O'Connor L
J Pharmacol Exp Ther; 1993 Jan; 264(1):47-53. PubMed ID: 8380870
[TBL] [Abstract][Full Text] [Related]
8. Involvement of kappa-opioid receptor mechanisms in the calcitonin-induced potentiation of opioid effects at the hypothalamus-pituitary-adrenocortical axis.
Milanés MV; Vargas ML; Martín MI
Eur J Pharmacol; 1994 Dec; 271(1):103-9. PubMed ID: 7698193
[TBL] [Abstract][Full Text] [Related]
9. The role of endogenous opioids in neurohypophysial and hypothalamo-pituitary-adrenal axis hormone secretory responses to stress in pregnant rats.
Douglas AJ; Johnstone HA; Wigger A; Landgraf R; Russell JA; Neumann ID
J Endocrinol; 1998 Aug; 158(2):285-93. PubMed ID: 9771473
[TBL] [Abstract][Full Text] [Related]
10. Chronic brain glucocorticoid receptor blockade enhances the rise in circadian and stress-induced pituitary-adrenal activity.
van Haarst AD; Oitzl MS; Workel JO; de Kloet ER
Endocrinology; 1996 Nov; 137(11):4935-43. PubMed ID: 8895366
[TBL] [Abstract][Full Text] [Related]
11. Roles of type I and II corticosteroid receptors in regulation of basal activity in the hypothalamo-pituitary-adrenal axis during the diurnal trough and the peak: evidence for a nonadditive effect of combined receptor occupation.
Bradbury MJ; Akana SF; Dallman MF
Endocrinology; 1994 Mar; 134(3):1286-96. PubMed ID: 8119168
[TBL] [Abstract][Full Text] [Related]
12. Catecholaminergic mediation of morphine-induced activation of pituitary-adrenocortical axis in the rat: implication of alpha- and beta-adrenoceptors.
Martinez-Piñero MG; Milanés MV; Alcaraz C; Vargas ML
Brain Res; 1994 Dec; 668(1-2):122-8. PubMed ID: 7704598
[TBL] [Abstract][Full Text] [Related]
13. ACTH and corticosterone response to naloxone and morphine in normal, hypophysectomized and dexamethasone-treated rats.
Jezová D; Vigas M; Jurcovicová J
Life Sci; 1982 Jul; 31(4):307-14. PubMed ID: 6292645
[TBL] [Abstract][Full Text] [Related]
14. Effects of specific mu and kappa opiate tolerance and abstinence on hypothalamo-pituitary-adrenal axis secretion in the rat.
Ignar DM; Kuhn CM
J Pharmacol Exp Ther; 1990 Dec; 255(3):1287-95. PubMed ID: 2175800
[TBL] [Abstract][Full Text] [Related]
15. Kappa opiate agonists modulate the hypothalamic-pituitary-adrenocortical axis in the rat.
Iyengar S; Kim HS; Wood PL
J Pharmacol Exp Ther; 1986 Aug; 238(2):429-36. PubMed ID: 3016237
[TBL] [Abstract][Full Text] [Related]
16. Plasma corticosterone changes in response to central or peripheral administration of kappa and sigma opiate agonists.
Eisenberg RM
J Pharmacol Exp Ther; 1985 Jun; 233(3):863-9. PubMed ID: 2989500
[TBL] [Abstract][Full Text] [Related]
17. The nociceptin/orphanin FQ antagonist UFP-101 differentially modulates the glucocorticoid response to restraint stress in rats during the peak and nadir phases of the hypothalamo-pituitary-adrenal axis circadian rhythm.
Leggett JD; Jessop DS; Fulford AJ
Neuroscience; 2007 Jul; 147(3):757-64. PubMed ID: 17574767
[TBL] [Abstract][Full Text] [Related]
18. Modulation by catecholamine of hypothalamus-pituitary-adrenocortical (HPA) axis activity in morphine-tolerance and withdrawal.
Martinez-Piñero MG; Milanes MV; Vargas ML
Gen Pharmacol; 1994 Jan; 25(1):187-92. PubMed ID: 8026704
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of protein kinase C but not protein kinase A attenuates morphine withdrawal excitation of rat hypothalamus-pituitary-adrenal axis.
Cerezo M; Laorden ML; Milanés MV
Eur J Pharmacol; 2002 Sep; 452(1):57-66. PubMed ID: 12323385
[TBL] [Abstract][Full Text] [Related]
20. Alpha-interferon inhibits adrenocortical secretion via mu 1-opioid receptors in the rat.
Saphier D; Welch JE; Chuluyan HE
Eur J Pharmacol; 1993 May; 236(2):183-91. PubMed ID: 8391456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
